Description

Rosuvastatin Calcium (BANM, JAN, USAN) is known as Rosuvastatin in the US. and a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM[1]. Rosuvastatin Calcium potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals[2]. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[3].

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

In the US, Rosuvastatin (rosuvastatin systemic) is a member of the drug class statins and is used to treat Atherosclerosis, High Cholesterol, High Cholesterol - Familial Heterozygous, High Cholesterol - Familial Homozygous, Hyperlipoproteinemia, Hyperlipoproteinemia Type IIa - Elevated LDL, Hyperlipoproteinemia Type IIb - Elevated LDL VLDL, Hyperlipoproteinemia Type III - Elevated beta-VLDL IDL, Hyperlipoproteinemia Type IV - Elevated VLDL, Hypertriglyceridemia and Prevention of Cardiovascular Disease.

Background

A selective, competitive inhibitor of HMG-CoA reductase, that is also antilipemic.

Storage

Chemical structure